

Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2020

https://marketpublishers.com/r/C1F45009D439EN.html

Date: August 2020

Pages: 75

Price: US\$ 3,500.00 (Single User License)

ID: C1F45009D439EN

Abstracts

Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2020

Summary

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1 and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Dermatology and Infectious Disease which include indications Migraine, Trigeminal Neuralgia (Tic Douloureux), Coronavirus Disease 2019 (COVID-19), Resistant Hypertension, Rosacea and Tension -Type Headache.

The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2020, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like



Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects



The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Overview

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

Avalyn Pharma Inc

Boehringer Ingelheim International GmbH

Fratagene Therapeutics Srl

Lead Discovery Center GmbH

Prous Institute for Biomedical Research SA

TopiVert Ltd

Turning Point Therapeutics Inc

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Drug Profiles

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress



ilorasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JRP-890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nintedanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Dormant Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Discontinued Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or

SRC or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by AbbVie Inc, H2 2020

Pipeline by AstraZeneca Plc, H2 2020

Pipeline by Avalyn Pharma Inc, H2 2020

Pipeline by Boehringer Ingelheim International GmbH, H2 2020

Pipeline by Fratagene Therapeutics Srl, H2 2020

Pipeline by Lead Discovery Center GmbH, H2 2020

Pipeline by Prous Institute for Biomedical Research SA, H2 2020

Pipeline by TopiVert Ltd, H2 2020

Pipeline by Turning Point Therapeutics Inc, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Dormant Products, H2 2020 (Contd..2), H2 2020

Discontinued Products, H2 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020

COMPANIES MENTIONED

Adepthera LLC
Allergan Ltd
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Sosei Heptares

Number of Products by Stage and Molecule Type, H2 2020



I would like to order

Product name: Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H2 2020

Product link: https://marketpublishers.com/r/C1F45009D439EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C1F45009D439EN.html